Ipamorelin Guide: Selective GH Secretagogue, Reported Dosing & Reconstitution

Ipamorelin at a glance

What it is

Ipamorelin — a selective synthetic pentapeptide agonist of the ghrelin receptor (GHS-R1a), classed as a growth-hormone-releasing peptide (GHRP).

Researched for

Growth-hormone secretagogue research; originally studied (and discontinued) for post-operative ileus.

Commonly reported range

~100–300 mcg per dose (community-reported).

Route reported

Subcutaneous injection.

Reported frequency

1–3 times per day, often fasted or at bedtime.

Reported cycle

~8–12 weeks.

Plasma half-life

Reported ~2 hours.

Regulatory status

Not FDA-approved; development discontinued after a negative Phase 2 trial; WADA-prohibited; research/educational use only.

Reported ranges from research/community — examples, not recommendations.

What it is / mechanism

Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that selectively agonizes the ghrelin receptor (GHS-R1a) on pituitary somatotrophs, triggering a signaling cascade that produces a pulsatile release of growth hormone, while also blunting somatostatin — the body's natural GH-inhibiting signal. Its defining trait in the research literature is selectivity: unlike older GHRPs such as GHRP-6 or GHRP-2, ipamorelin is reported to release GH without meaningfully raising cortisol, prolactin, ACTH, or aldosterone, and with only minimal appetite stimulation.

Researched effects

Preclinical research consistently demonstrates selective GH release. The one completed human randomized trial (Beck et al., 2014, roughly 114 patients studied for post-operative ileus) missed its primary endpoint (p≈0.15). Body-composition, recovery, or anti-aging effects sometimes discussed in community reports have not been demonstrated in controlled human trials, and no Phase 3 program exists. These are research findings and reported community experience, not guaranteed outcomes.

Dosage — reported ranges (overview)

Community-reported ranges commonly cluster around 100–300 mcg per dose, given one to three times per day — frequently 200–300 mcg standalone at bedtime, or split as 100 mcg paired with 100 mcg of CJC-1295. Fasted administration (empty stomach) is commonly described, since food intake is thought to blunt the GH pulse. These are examples of what is reported, not a recommendation; there is no FDA-approved human dose.

A printable protocol sheet with a reconstitution reference and an injection log comes with All-Access Lifetime.

Reconstitution — bac-water math

Ipamorelin ships lyophilized and is reconstituted with bacteriostatic water. Concentration (mcg per mL) = total mcg in the vial ÷ mL of bac water added; on a U-100 insulin syringe (100 units = 1 mL), syringe units for a dose = dose ÷ concentration × 100. Worked example for a 5 mg vial:

This is concentration math, not a dose recommendation.

Injection / administration basics

Reported administration is subcutaneous (abdomen, flank, or thigh) using a U-100 insulin syringe, with site rotation commonly described; dosing is often reported fasted, frequently at bedtime to align with the nocturnal GH surge. General handling concepts — sterile technique, site rotation, timing — are covered here as general information; the detailed workflow comes with All-Access Lifetime, which includes the printable protocol sheet and injection log for every compound. This is general educational information, not a personal administration protocol; a qualified professional should guide any actual use.

Half-life & frequency rationale

Ipamorelin's plasma half-life is reported at roughly 2 hours — long enough to sustain a GH pulse but cleared well before a next reported dose, which is why community protocols describe one to three doses per day rather than a single daily dose, aiming to preserve receptor sensitivity and mimic a more natural pulsatile rhythm.

Stacking — overview

Ipamorelin paired with CJC-1295 (no-DAC) is the classic GH-axis combination in the research literature and community reports — often sold pre-blended at 5 mg/5 mg — because a GHRP and a GHRH act on different receptors. It is also described as complementary (not redundant) with tesamorelin or sermorelin, since both of those are GHRH analogs that pair with ipamorelin's GHRP action rather than duplicating it.

For how combinations are grouped by research context, the named blends, and why a pre-mixed blend vial cannot be calculated from its total milligrams, see the peptide stacks guide.

Storage & handling

• Lyophilized (unmixed): store cold and dark; long-term typically frozen.
• Reconstituted: refrigerate (~2–8°C); commonly reported usable window ~2–3 weeks; swirl gently, do not shake; do not freeze once mixed.

Evidence File

The Ipamorelin Evidence File: Two Completed Phase 2 Trials, One of Them Published

Ipamorelin's public record is small enough to be enumerated completely, and this module enumerates it: every ClinicalTrials.gov record returned under the drug name, the salt name and the Novo Nordisk development code, and every PubMed record filed under the word ipamorelin, inspected one at a time. It sets out what each human study measured, in whom, by which route and at what dose; converts the trial doses into units that can be compared with the figures circulating in community protocols; traces five widely repeated numbers back to the specific document each came from; and states every absence alongside the exact searches that established it.

• 2 completed Phase 2 trials, 437 patients enrolled between them
• Both Phase 2 trials infused ipamorelin, and neither used the community route
• 5 circulating figures traced back to their origin documents
• 1.2 to 9.0 mg per trial infusion, against 100-300 mcg reported

Sourcing File

Sourcing Ipamorelin: The Identity Line, the Acetate Arithmetic and Four Named Adulterants

A generic warning that peptides can be counterfeit is worth very little. This module replaces it with numbers specific to ipamorelin: the identity values a certificate has to match, cross-checked between PubChem and the FDA substance registry; the acetate arithmetic that decides how much peptide a labelled milligram actually contains, checked against three separately registered salt forms; the exact mass shift of the one adulterant that forensic laboratories have named for this molecule, alongside the near-mass species that sit close enough to the parent to be missed; and the one failure mode built into ipamorelin's own structure that no mass-spectrometry line on any certificate can detect.

• 3 acetate stoichiometries registered; a 5 mg label spans 4.61 to 3.99 mg
• Gly-ipamorelin, plus 57.02 Da, named in two forensic laboratories' material
• 2 D-amino acids that no identity-by-MS line can verify
• [M+H]+ 712.39; a peak at 769.41 or 754.40 is a different molecule

Benefit & Outcome Review

Ipamorelin Claim by Claim: Twelve Marketed Outcomes, Graded Against What Was Measured

Ipamorelin is sold on a list of outcomes that the free guide can only describe as community-reported. This module takes each of those outcomes in turn and asks four questions of the underlying paper: what was measured, in which species, against which comparator, and for how long. Every claim is then assigned an evidence tier, from a controlled human study through animal and cell work down to claims with no measurement behind them at all. Several of the supporting studies turn out to say something other than what is attributed to them, and one of them points in the opposite direction.

• 2 of 12 graded claims have any human measurement behind them
• Longest documented human exposure: roughly one to two weeks
• The only direct fat measurement gained relative fat, in mice
• The only IGF-1 measurement found no change, in rats

Guide FAQ

Quick answers about guide scope, access, and educational use context.